Geron (GERN) Free Cash Flow (2010 - 2026)
Geron (GERN) posted Free Cash Flow of -$62.9 million for Q1 2026, down 185.07% sequentially from -$22.1 million in Q4 2025, and down 31.11% YoY from -$91.3 million in Q1 2025.
Geron (GERN) Free Cash Flow (2010 - 2026) Analysis & Trends
Geron has reported Free Cash Flow for 17 years, with the latest figure at -$62.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 31.11% year-over-year to -$62.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$126.0 million (up 38.31% YoY) and the FY2025 annual result came in at -$111.0 million, up 49.37% from the prior year.
- Free Cash Flow eased to -$62.9 million in Q1 2026 per GERN's latest filing, from -$22.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$13.6 million in Q3 2025 and troughed at -$63.1 million in Q1 2024.
- A 5-year average of -$40.6 million and a median of -$41.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 109.44% in 2023, then surged 76.97% in 2025.
- Over 5 years, Free Cash Flow stood at -$35.3 million in 2022, then dropped by 16.08% to -$41.0 million in 2023, then declined by 6.83% to -$43.8 million in 2024, then jumped by 49.62% to -$22.1 million in 2025, then tumbled by 185.07% to -$62.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$62.9 million, -$22.1 million, and -$13.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -15.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.83 Mn |
| Jun 30, 2026 | -15.83 Mn |
| Mar 31, 2026 | -62.91 Mn |
| Mar 31, 2026 | -62.91 Mn |
| Dec 31, 2025 | -22.07 Mn |
| Dec 31, 2025 | -22.07 Mn |
| Sep 30, 2025 | -13.58 Mn |
| Sep 30, 2025 | -13.58 Mn |
| Jun 30, 2025 | -27.42 Mn |
| Jun 30, 2025 | -27.42 Mn |
| Mar 31, 2025 | -47.98 Mn |
| Mar 31, 2025 | -47.98 Mn |
| Dec 31, 2024 | -43.80 Mn |
| Dec 31, 2024 | -43.80 Mn |
| Sep 30, 2024 | -58.94 Mn |
| Sep 30, 2024 | -58.94 Mn |
| Jun 30, 2024 | -53.48 Mn |
| Jun 30, 2024 | -53.48 Mn |
| Mar 31, 2024 | -63.07 Mn |
| Mar 31, 2024 | -63.07 Mn |